Ferroptosis-Related lncRNAs Act as Novel Prognostic Biomarkers in the Gastric Adenocarcinoma Microenvironment, Immunotherapy, and Chemotherapy
Oxidative Medicine and Cellular Longevity · 2023
DOI: 10.1155/2023/9598783 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oxidative Medicine and Cellular Longevity, 2023. Verfasst von Yushi Zheng und 3 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical College, Guangdong Medical University, Zhanjiang, Guangdong 524023, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, RNA, Long Noncoding, Ferroptosis, Adenocarcinoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Public Service Platform of South China Sea for R&D Marine Biomedicine Resources, Medical Scientific Research Foundation of Guangdong Province of China, Guangdong Medical University.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Ferroptosis, a form of programmed cell death akin to necrosis, is managed by iron and is distinguished by lipid peroxidation. Gastric cancer is a highly aggressive form of cancer, responsible for the third highest number of cancer-related deaths globally. Despite this, the potential of ferroptosis to predict the occurrence of this cancer is yet to be determined. In this research, a comprehensive examination was conducted to explore the link between long noncoding RNAs (lncRNAs) and ferroptosis, in order to uncover an lncRNA signature that can predict drug susceptibility and tumor mutational burden (TMB) in gastric adenocarcinoma. We conducted an in-depth analysis of the GC immune microenvironment and immunotherapy, with a particular focus on ferroptosis-related lncRNA prognostic biomarkers, and further explored the correlation between these factors and prognosis, immune infiltration, single nucleotide variation (SNV), and drug sensitivity for gastric adenocarcinoma patients. Through our investigations, we have discovered five lncRNA signatures related to ferroptosis that can accurately forecast the prognosis of gastric adenocarcinoma patients and also regulate the proliferation, migration, and occurrence of ferroptosis in gastric adenocarcinoma cells. In conclusion, this lncRNA signature associated with ferroptosis may be employed as a prognostic indicator for gastric adenocarcinoma, thus presenting a potential solution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The First Clinical College, Guangdong Medical University, Zhanjiang, Guangdong 524023, China.
- Department of Biology, School of Basic Medical Science, Guangdong Medical University, Zhanjiang, Guangdong 524023, China.
- The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, Guangdong 524023, China.
- The Marine Biomedical Research Institute of Guangdong Zhanjiang, Zhanjiang, Guangdong 524023, China.
ORCID-Profile: Lianxiang Luo
Förderung
- Public Service Platform of South China Sea for R&D Marine Biomedicine Resources
- Medical Scientific Research Foundation of Guangdong Province of China
- Guangdong Medical University
- Guangzhou Science and Technology Program key projects
Zitieren
APA
Zheng, Y., Wu, S., Huang, X., & Luo, L. (2023). Ferroptosis-Related lncRNAs Act as Novel Prognostic Biomarkers in the Gastric Adenocarcinoma Microenvironment, Immunotherapy, and Chemotherapy. Oxidative Medicine and Cellular Longevity. https://doi.org/10.1155/2023/9598783
Vancouver
Zheng Y, Wu S, Huang X, Luo L. Ferroptosis-Related lncRNAs Act as Novel Prognostic Biomarkers in the Gastric Adenocarcinoma Microenvironment, Immunotherapy, and Chemotherapy. Oxidative Medicine and Cellular Longevity. 2023. doi:10.1155/2023/9598783
BibTeX
@article{Zheng2023,
author = {Zheng, Yushi and Wu, Shanshan and Huang, Xueshan and Luo, Lianxiang},
title = {Ferroptosis-Related lncRNAs Act as Novel Prognostic Biomarkers in the Gastric Adenocarcinoma Microenvironment, Immunotherapy, and Chemotherapy},
journal = {Oxidative Medicine and Cellular Longevity},
year = {2023},
doi = {10.1155/2023/9598783}
}
EUVIMED